Your Brain Matter, Matters
When it comes to brain health, you and your loved ones deserve as much clarity and accuracy as possible. That’s why Qynapse is dedicated to providing you and your physician with an objective view of your brain health.
Clarity, precision and results you can trust for more peace of mind.
For those facing the onset of a central nervous system (CNS) disease, such as Alzheimer’s, Parkinson’s and multiple sclerosis, and for those wondering if one is on the horizon, Qynapse offers a clearer and more objective view of your brain health.
QyScore®, our FDA-Cleared, CE-marked neuroimaging software platform, takes an MRI scan, applies our high-performing algorithms, rapidly analyzes, compares to age-matched controls and produces automated brain measures in an easy-to-use patient report. This offers your healthcare provider precise, accurate and objective data that has the potential to reduce the time to diagnosis, facilitate smooth therapeutic switches and personalize your long-term care plan.
With a better understanding of your MRI scans earlier, your physician can recommend timely intervention methods to you and your loved ones which could improve your quality of life and outcome with fewer clinical visits. Empower planning with more clarity, earlier.
Our technology is a game changer.
QyScore® is FDA-Cleared and CE-Marked
Better Awareness
Potential to increase patient and caregiver awareness of diagnosis
Time to Diagnosis
Qynapse has the potential to reduce time to diagnosis
Timely Intervention
Potential to support early intervention and better patient outcomes
Marwan N. Sabbagh
MD, FAAN, CCRI
Going from a diagnostic accuracy of 66-70% to better than 90% is today the most pressing topic for the Alzheimer’s disease community. I am glad to see innovative organizations like Qynapse leading the way and contributing to transform the diagnosis of Alzheimer’s disease.
David Merrill, MD, PhD
Director | Pacific Brain Health Center Pacific Neuroscience Institute
I’m excited to use QyScore® to quantify both volumetric and white matter integrity in our patients – bringing such an important layer of precision and objectivity to inform our clinical decisions.
Olivier Courrèges
Founder & CEO | Qynapse
When someone you love is declining mentally, there's nothing worse than not having a clear diagnosis as to why. That's why Qynapse is on a mission to transform time to diagnosis and the accuracy for diagnosis for CNS disease.
Srinivas Peddi, MD
Radiologist & Board Member | Tower Imaging Medical Group
When you remove air from a ball, it’s hard to figure that out until it’s lost a lot of volume. But if we had a tool that would let us measure more precisely? That’s super helpful. And that's what Qynapse provides.
Diane Souza
Former CEO | UnitedHealthcare Specialty Benefits
Payers have developed very sophisticated systems and data sets to help their members, healthcare providers and teams make better decisions about healthcare. What Qynapse provides further enhances that decision making, resulting from the whole being greater than the sum of the parts.
Bruno Dubois, MD, PhD
Professor of Neurology | Sorbonne University, Director of the Institute of Memory and Alzheimer’s Disease (IM2A) | Pitié Salpêtrière Hospital in Paris
In light of the recent breakthrough for Alzheimer’s patients – the approval of new treatment options by the FDA, Qynapse’s vision is becoming even more critical to advance the early detection of Alzheimer’s disease and to precisely monitor the therapy efficacy and safety.
Your brain matter, matters. Qynapse provides you and your health practitioner a clearer and more objective view of your brain health.
Qyscore® is a medical device software FDA-cleared – class II and CE-marked – class IIa.
Indications for Use in the U.S. (FDA): QyScore® is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures and lesions from a set of MR images. Volumetric data may be compared to reference percentile data. QyScore® is not intended for use in clinical scenarios that require evaluation of the number of the white matter hyperintensities.
Indications for Use in Europe (CE): QyScore® is an advanced processing and visualization software for automatic labeling and volumetric quantification of segmented central nervous system structures for patients older than 18 years of age. The software is intended to be used by medical personnel or neuroimaging trained personnel to support diagnosis of central nervous system diseases.